Zoetis Inc. will conduct an Innovation Webcast on December 2, 2025, where key executives will discuss the company's pipeline and strategic approach to animal health.
The webcast will feature insights from Dr. Kevin Esch, who will succeed Dr. Rob Polzer as President of Research and Development effective January 1, 2026. This leadership transition is expected to bring fresh perspectives to Zoetis' research initiatives.
As a leading animal health company, Zoetis generated $9.3 billion in revenue in 2024 and employs approximately 13,800 people. The webcast aims to highlight the company's commitment to advancing care for animals.
Investors can access the live webcast via the Zoetis website, with pre-registration available. A replay will also be provided after the event.
Wall Street analysts forecast ZTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZTS is 154.20 USD with a low forecast of 130.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast ZTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZTS is 154.20 USD with a low forecast of 130.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 121.930
Low
130.00
Averages
154.20
High
200.00
Current: 121.930
Low
130.00
Averages
154.20
High
200.00
UBS
Neutral
downgrade
$141 -> $136
2026-01-29
New
Reason
UBS
Price Target
$141 -> $136
AI Analysis
2026-01-29
New
downgrade
Neutral
Reason
UBS lowered the firm's price target on Zoetis to $136 from $141 and keeps a Neutral rating on the shares.
Piper Sandler
David Westenberg
Overweight -> Neutral
downgrade
$190 -> $135
2026-01-22
Reason
Piper Sandler
David Westenberg
Price Target
$190 -> $135
2026-01-22
downgrade
Overweight -> Neutral
Reason
Piper Sandler analyst David Westenberg downgraded Zoetis to Neutral from Overweight with a price target of $135, down from $190.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ZTS
Unlock Now
Piper Sandler
Overweight -> Neutral
downgrade
$190 -> $135
2026-01-22
Reason
Piper Sandler
Price Target
$190 -> $135
2026-01-22
downgrade
Overweight -> Neutral
Reason
Piper Sandler downgraded Zoetis to Neutral from Overweight with a price target of $135, down from $190. The firm continues to like Zoetis' portfolio over the long term, but is not comfortable with estimates over the next couple of years until it sees some of the company's innovation hitting the market. Zoetis "is in an innovation air pocket that could last one to two years," the analyst tells investors in a research note. Further, Piper does not believe the current consumer spending environment supports the price versus value the company's 2026 launches provide.
Morgan Stanley
Overweight
downgrade
$175 -> $160
2025-12-18
Reason
Morgan Stanley
Price Target
$175 -> $160
2025-12-18
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Zoetis to $160 from $175 and keeps an Overweight rating on the shares. For healthcare technology and providers, the firm sees an "attractive backdrop for alpha-generation opportunities" in 2026, the analyst tells investors. Meanwhile, managed care stocks have underperformed in 2025 and are facing "another year of unprecedented policy, reimbursement, and utilization headwinds," the analyst added in a year-ahead outlook note for the Healthcare Services group.
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
